Table 1.
Patients' characteristics and transmission of KPC-KP
| November 2019–February 2020 | March 2020–August 2020 | P a | |
|---|---|---|---|
| Hospitalized patients, n | 80 | 123 | |
| Age, years, median (range) | 56 (23–81) | 60 (22–80) | 0.08 |
| Male, n (%) | 39 (49) | 68 (55) | 0.3 |
| Underlying disease, n (%) | |||
| Acute leukaemia | 35 (48) | 46 (38) | 0.3 |
| Lymphoma | 27 (30) | 48 (39) | |
| Multiple myeloma | 12 (15) | 14 (11) | |
| Other | 6 (7) | 15 (12) | |
| Reason for hospitalization, n (%) | |||
| High-dose chemotherapy | 36 (45) | 52 (43) | 0.2 |
| Autologous SCT | 20 (25) | 24 (21) | |
| Immunotherapy | 6 (8) | 12 (8) | |
| Other | 15 (22) | 35 (28) | |
| Patients previously submitted to allogeneic SCT, n (%) | 6 (7) | 7 (6) | 0.6 |
| Hospitalizations per patient, n (range) | 2 (1–5) | 2 (1–6) | |
| Total KPC-KP-positive patients, n (%) | 42 (52.5) | 19 (15.5) | <0.001 |
| New KPC-KP-positive patients | 22 (27.5) | 10 (8) | 0.0003 |
| Patients known to be KPC-KP positive at hospitalization | 20 (25) | 9 (7.5) | |
| Patients who developed febrile neutropenia during hospitalization, n (%) | 58 (72) | 80 (65) | 0.2 |
| KPC-KP bloodstream infections, n (%) | 7 (8) | 4 (3) | 0.02 |
| KPC-KP bloodstream infections developed in KPC-KP carriers, n/N (%) | 7/42 (17) | 4/19 (21) | 0.7 |
| Deaths for any reason, n (%) | 9 (11) | 13 (10.5) | 0.5 |
| KPC-KP-related death | 1 (1) | 0 | |
| Ceftazidime/avibactam | |||
| Total consumption, vials | 940 | 740 | |
| Median consumption/month, vials | 245 | 110 | 0.03 |
| Total DOT | 313 | 247 | |
| Mean DOT/month | 81 | 36 | 0.002 |
| Median cost/month, € | 19 550 | 10 000 | 0.03 |
SCT, stem cell transplant.
a
Median values of the two periods were compared using the Mann–Whitney test.